This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stift, A. Articles by Friedl, J. Search for Related Content PubMed PubMed Citation Articles by Stift, A. Articles by Friedl, J.

Dendritic Cell Vaccination in Medullary Thyroid Carcinoma

¹ Department of Surgery, University of Vienna, Medical School, Vienna, Austria; ² Baylor Institute for Immunology Research, Dallas, Texas; and ³ Department of Pathophysiology, University of Graz, Medical School, Graz, Austria

Purpose: Prognosis and treatment effectiveness for medullary thyroid carcinoma (MTC) are strictly related to tumor stage. Palliative treatment options show no significant benefit. A promising treatment approach for human cancer is based on the vaccination of autologous dendritic cells (DCs).

Experimental Design: The objective of this study was to evaluate the effectiveness of DC vaccines in MTC patients. Therefore, we generated autologous tumor lysate-pulsed DCs from 10 patients suffering from advanced MTC for repeated vaccination. Mature DCs were derived from peripheral blood monocytes by using CD14 magnetic bead selection and subsequent culture in the presence of granulocyte macrophage colony-stimulating factor, interleukin 4, and tumor necrosis factor with or without addition of IFN-. DCs were loaded with tumor lysate and further injected into a groin lymph node. Toxicity, tumor marker profile, immune response, and clinical response were determined.

Results: Vaccination was well tolerated and induced a positive immunological response in all of the tested patients as evaluated by in vivo delayed-type hypersensitivity reactivity or in vitro intracytoplasmic IFN- detection assay. Three patients had a partial response, 1 patient presented a minor response, and 2 patients showed stable disease. The remaining 4 patients had progressive disease.

Conclusions: These data provide strong evidence that vaccination with tumor-lysate pulsed DCs results in the induction of a specific immune response in patients suffering from MTC. Objective clinical responses could be observed even for far-advanced disease. Therefore, we suggest that MTC is particularly suited for DC-based immunotherapy.

This article has been cited by other articles:

				T. Bachleitner-Hofmann, M. Strohschneider, P. Krieger, M. Sachet, P. Dubsky, H. Hayden, S. F. Schoppmann, R. Pfragner, M. Gnant, J. Friedl, et al. Heat Shock Treatment of Tumor Lysate-Pulsed Dendritic Cells Enhances Their Capacity to Elicit Antitumor T Cell Responses against Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4571 - 4577. [Abstract] [Full Text] [PDF]

				M. Schott Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr. Relat. Cancer, September 1, 2006; 13(3): 779 - 795. [Abstract] [Full Text] [PDF]

				L. S. Kirschner Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21. [Abstract] [Full Text] [PDF]

				R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano, T. Kobayashi, S. Yoshida, T. Abe, M. Narita, M. Takahashi, et al. Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial Clin. Cancer Res., June 1, 2005; 11(11): 4160 - 4167. [Abstract] [Full Text] [PDF]

				R. Stein and D. M. Goldenberg A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy Mol. Cancer Ther., December 1, 2004; 3(12): 1559 - 1564. [Abstract] [Full Text] [PDF]